

235 Assessed for eligibility

110 Randomized

125 excluded
102 inclusion criteria
12 refused to participate
11 were not enrolled for other reasons

46 allocated to Calcium Acetate
All received allocated intervention

64 allocated to Placebo
All received allocated intervention

18 early discontinued subjects

Reason for discontinuation

	0-12 weeks	After 12 weeks
	n	n
Death	1	0
Lost to follow-up	0	0
Non-compliance	1	1
Protocol violation	0	0
Withdraw consent	3	0
Adverse event	2	3
Failure to control phos	0	4
Other	2	1
Subtotal	9	9

Completed by Week 12 (n=37)

Completed study (n=28)

44 discontinued subjects

Reason for discontinuation

	0-12 weeks	After 12 weeks
	n	n
Death	1	2
Lost to follow-up	0	1
Non-compliance	3	0
Protocol violation	7	0
Withdraw consent	2	1
Adverse event	4	2
Failure to control phos	2	15
Other	4	0
Subtotal	23	21

Completed by Week 12 (n=41)

Completed study (n=20)